YU34269B - Process for preparing delta-alkylamino-propiophenones - Google Patents

Process for preparing delta-alkylamino-propiophenones

Info

Publication number
YU34269B
YU34269B YU2945/70A YU294570A YU34269B YU 34269 B YU34269 B YU 34269B YU 2945/70 A YU2945/70 A YU 2945/70A YU 294570 A YU294570 A YU 294570A YU 34269 B YU34269 B YU 34269B
Authority
YU
Yugoslavia
Prior art keywords
propiophenones
alkylamino
preparing delta
delta
preparing
Prior art date
Application number
YU2945/70A
Other languages
English (en)
Other versions
YU294570A (en
Inventor
Metha Nariman Bomanshaw
Nariman Bomanshaw Metha
Yeowell David Arthur
David Arthur Yeowell
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10483336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU34269(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of YU294570A publication Critical patent/YU294570A/xx
Publication of YU34269B publication Critical patent/YU34269B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • C07C49/807—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen all halogen atoms bound to the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/63—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
YU2945/70A 1969-12-04 1970-12-03 Process for preparing delta-alkylamino-propiophenones YU34269B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB5923169 1969-12-04

Publications (2)

Publication Number Publication Date
YU294570A YU294570A (en) 1978-10-31
YU34269B true YU34269B (en) 1979-04-30

Family

ID=10483336

Family Applications (1)

Application Number Title Priority Date Filing Date
YU2945/70A YU34269B (en) 1969-12-04 1970-12-03 Process for preparing delta-alkylamino-propiophenones

Country Status (29)

Country Link
US (1) US3819706A (xx)
JP (1) JPS4825179B1 (xx)
AR (2) AR192302A1 (xx)
AT (2) AT302276B (xx)
BE (1) BE759838A (xx)
CA (1) CA977777A (xx)
CH (2) CH574907A5 (xx)
CS (1) CS172338B2 (xx)
DE (2) DE2064934A1 (xx)
DK (1) DK134984B (xx)
EG (1) EG10507A (xx)
ES (1) ES386127A1 (xx)
FI (1) FI53813C (xx)
FR (1) FR2081326B1 (xx)
HK (1) HK78476A (xx)
IE (1) IE34788B1 (xx)
IL (1) IL35781A (xx)
IT (1) IT8047948A0 (xx)
MT (1) MTP680B (xx)
MY (1) MY7700107A (xx)
NL (1) NL172148C (xx)
NO (1) NO131127C (xx)
PH (1) PH9351A (xx)
PL (1) PL74637B1 (xx)
RO (1) RO57979A (xx)
SE (1) SE377933B (xx)
YU (1) YU34269B (xx)
ZA (1) ZA708179B (xx)
ZM (1) ZM14070A1 (xx)

Families Citing this family (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021492A (en) * 1975-03-24 1977-05-03 Sandoz, Inc. Dibromination process
SE414305B (sv) * 1976-08-25 1980-07-21 Astra Laekemedel Ab Analogiforfarande for framstellning av eventuellt substituerade 2-amino-6-fenyl-5,5dimetyl 3-hexanon med antidepressiv aktivitet
US4318791A (en) * 1977-12-22 1982-03-09 Ciba-Geigy Corporation Use of aromatic-aliphatic ketones as photo sensitizers
FR2430933A1 (fr) * 1978-07-13 1980-02-08 Synthelabo Derives de propiophenone et leur application en therapeutique
US4347257A (en) * 1979-10-09 1982-08-31 Burroughs Wellcome Co. Prolactin suppression in mammals
FR2486074A1 (fr) * 1979-12-14 1982-01-08 Lafon Labor Derives de fluorophenacyl-amine, leur procede de preparation et leur application en therapeutique
AU549908B2 (en) * 1980-04-14 1986-02-20 Wellcome Foundation Limited, The Labelled t-butylamino propiophenone derivatives immunogens, antisera, radio immunoassay method and test kit
EP0060954B1 (fr) * 1981-03-23 1984-08-15 LABORATOIRE L. LAFON Société anonyme dite: Dérivés de fluorophénacyl-amine, et leur application en thérapeutique
JPS57169450A (en) * 1981-04-13 1982-10-19 Lafon Labor Fluorophenacyl-amine derivative and application to remedy
US4393078A (en) * 1982-03-15 1983-07-12 Burroughs Wellcome Co. Bupropion and ethanol
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
US4507323A (en) * 1984-07-25 1985-03-26 Burroughs Wellcome Co. Treatment of psychosexual dysfunctions
FR2569185B1 (fr) * 1984-08-20 1986-09-05 Lafon Labor Derives de 1-(aminophenyl)-2-amino-ethanone, procede de preparation et utilisation en therapeutique
US5236922A (en) * 1984-08-20 1993-08-17 Laboratoire L. Lafon Method for treating depression using 1-(aminophenyl)-2-aminopropanone derivatives
FR2569184A1 (fr) * 1984-08-20 1986-02-21 Lafon Labor Derives de 1-(aminophenyl) therapeutique et leur procede de preparation
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) * 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) * 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) * 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
WO1995022324A1 (en) * 1994-02-18 1995-08-24 Walter Pinsker Treatment of migraine headaches and formulations
US5753712A (en) * 1994-02-18 1998-05-19 Pinsker; Walter Treatment of migraine headaches and formulations
US6652882B1 (en) * 1997-10-06 2003-11-25 Intellipharmaceutics Corp Controlled release formulation containing bupropion
US5968553A (en) * 1997-12-30 1999-10-19 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
US6221917B1 (en) 1997-12-30 2001-04-24 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) * 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
WO1999038504A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
AU2349999A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmacological uses of pure (+) -bupropion
US6150420A (en) * 1998-06-01 2000-11-21 Theramax, Inc. Method for enhanced brain delivery of bupropion
US6153223A (en) * 1998-06-05 2000-11-28 Watson Pharmaceuticals, Inc. Stabilized pharmaceutical compositions
US6855820B2 (en) * 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6210716B1 (en) 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US6589553B2 (en) * 2001-02-08 2003-07-08 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
US6306436B1 (en) 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
US20030044462A1 (en) * 2001-08-20 2003-03-06 Kali Laboratories, Inc. Sustained release tablets containing bupropion hydrochloride
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US7109198B2 (en) * 2002-05-17 2006-09-19 Duke University Method for treating obesity
US6932971B2 (en) * 2002-07-18 2005-08-23 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof
WO2004024674A1 (en) * 2002-09-10 2004-03-25 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Process for the preparation of bupropion hydrochloride
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
ITMI20030762A1 (it) * 2003-04-11 2004-10-12 Erregierre Spa Processo di cristallizzazione del bupropione cloridrato.
PL1617832T3 (pl) * 2003-04-29 2009-01-30 Orexigen Therapeutics Inc Kompozycje wpływające na utratę wagi
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
EP2156863A3 (en) 2003-09-12 2011-01-12 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
CA2547283C (en) * 2003-11-26 2010-11-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
US20050176680A1 (en) 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US7429580B2 (en) 2004-01-13 2008-09-30 Orexigen Therapeutics, Inc. Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
ZA200711123B (en) * 2005-06-27 2009-08-26 Biovail Lab Int Srl Modified-release formulations of a bupropion salt
AU2006269231A1 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CN101374507A (zh) * 2005-10-14 2009-02-25 H.隆德贝克有限公司 含有依他普仑和安非他酮的稳定药物制剂
EA200801081A1 (ru) * 2005-10-14 2008-10-30 Х. Лундбекк А/С Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP3132792B1 (en) 2005-11-22 2019-09-11 Nalpropion Pharmaceuticals, Inc. Composition and methods for increasing insulin sensitivity
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007079470A2 (en) * 2006-01-03 2007-07-12 Algebra, Inc. Therapeutic amine-arylsulfonamide conjugate compounds
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2007360B1 (en) * 2006-04-03 2014-11-26 Isa Odidi Controlled release delivery device comprising an organosol coat
WO2007117581A2 (en) * 2006-04-06 2007-10-18 Collegium Pharmaceutical, Inc. Stabilized transdermal bupropion preparations
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US7674479B2 (en) * 2006-07-25 2010-03-09 Intelgenx Corp. Sustained-release bupropion and bupropion/mecamylamine tablets
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
KR101479324B1 (ko) 2006-11-09 2015-01-05 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
WO2008156749A1 (en) * 2007-06-18 2008-12-24 The General Hospital Corporation Combination therapy for depression
CN100560563C (zh) * 2007-07-06 2009-11-18 浙江普洛医药科技有限公司 盐酸安非他酮的合成方法
US20090076161A1 (en) 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched bupropion
US20090148541A1 (en) * 2007-10-16 2009-06-11 Duke University Compositions and methods for the treatment of seborrhea
WO2009111031A2 (en) * 2008-03-04 2009-09-11 Intra-Cellular Therapies, Inc. Methods of treating vasomotor symptoms
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US8450376B2 (en) * 2008-06-16 2013-05-28 Glenmark Generics Ltd. Amorphous bupropion hydrobromide and preparation thereof
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
JP5711724B2 (ja) 2009-04-15 2015-05-07 リサーチ・トライアングル・インスティチュート モノアミン再取り込み阻害剤
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
BR112012016783A2 (pt) 2010-01-11 2015-09-01 Orexigen Therapeutics Inc "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
LT2858640T (lt) 2012-06-06 2020-08-10 Nalpropion Pharmaceuticals Llc Kompozicija, skirta panaudoti pacientų su aukšta širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
US11129826B2 (en) 2013-11-05 2021-09-28 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US10940124B2 (en) 2019-01-07 2021-03-09 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10980800B2 (en) 2013-11-05 2021-04-20 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11147808B2 (en) 2013-11-05 2021-10-19 Antecip Bioventures Ii Llc Method of decreasing the fluctuation index of dextromethorphan
US11234946B2 (en) 2013-11-05 2022-02-01 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9402843B2 (en) 2013-11-05 2016-08-02 Antecip Bioventures Ii Llc Compositions and methods of using threohydroxybupropion for therapeutic purposes
US11253492B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11576909B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11291638B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11311534B2 (en) 2013-11-05 2022-04-26 Antecip Bio Ventures Ii Llc Bupropion as a modulator of drug activity
US10966941B2 (en) 2013-11-05 2021-04-06 Antecip Bioventures Ii Llp Bupropion as a modulator of drug activity
US11229640B2 (en) 2013-11-05 2022-01-25 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US10080727B2 (en) 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11285146B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9968568B2 (en) 2013-11-05 2018-05-15 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11298351B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11185515B2 (en) 2013-11-05 2021-11-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9867819B2 (en) 2013-11-05 2018-01-16 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11213521B2 (en) 2013-11-05 2022-01-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11123344B2 (en) 2013-11-05 2021-09-21 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US11357744B2 (en) 2013-11-05 2022-06-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9457023B1 (en) 2013-11-05 2016-10-04 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9707191B2 (en) 2013-11-05 2017-07-18 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11123343B2 (en) 2013-11-05 2021-09-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571399B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10864209B2 (en) 2013-11-05 2020-12-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10799497B2 (en) 2013-11-05 2020-10-13 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US9457025B2 (en) 2013-11-05 2016-10-04 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US11344544B2 (en) 2013-11-05 2022-05-31 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11291665B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10945973B2 (en) 2013-11-05 2021-03-16 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541048B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11058648B2 (en) 2013-11-05 2021-07-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298352B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617747B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9700528B2 (en) 2013-11-05 2017-07-11 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10772850B2 (en) 2013-11-05 2020-09-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10894047B2 (en) 2013-11-05 2021-01-19 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10933034B2 (en) 2013-11-05 2021-03-02 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11517543B2 (en) 2013-11-05 2022-12-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541021B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20200338022A1 (en) 2019-01-07 2020-10-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11273134B2 (en) 2013-11-05 2022-03-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11197839B2 (en) 2013-11-05 2021-12-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10105327B2 (en) 2013-11-05 2018-10-23 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
US9408815B2 (en) 2013-11-05 2016-08-09 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20160324807A1 (en) 2013-11-05 2016-11-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11576877B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as modulator of drug activity
US11364233B2 (en) 2013-11-05 2022-06-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11020389B2 (en) 2013-11-05 2021-06-01 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11096937B2 (en) 2013-11-05 2021-08-24 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10966942B2 (en) 2019-01-07 2021-04-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10105361B2 (en) 2013-11-05 2018-10-23 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9861595B2 (en) 2013-11-05 2018-01-09 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10966974B2 (en) 2013-11-05 2021-04-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10874663B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10894046B2 (en) 2013-11-05 2021-01-19 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10898453B2 (en) 2013-11-05 2021-01-26 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11253491B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20220233470A1 (en) 2013-11-05 2022-07-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426401B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11510918B2 (en) 2013-11-05 2022-11-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10874664B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9763932B2 (en) 2013-11-05 2017-09-19 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10780064B2 (en) 2019-01-07 2020-09-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426370B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11090300B2 (en) 2013-11-05 2021-08-17 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10813924B2 (en) 2018-03-20 2020-10-27 Antecip Bioventures Ii Llc Bupropion and dextromethorphan for treating nicotine addiction
US11524007B2 (en) 2013-11-05 2022-12-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9198905B2 (en) 2013-11-05 2015-12-01 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
US11065248B2 (en) 2013-11-05 2021-07-20 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11191739B2 (en) 2013-11-05 2021-12-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20160361305A1 (en) 2013-11-05 2016-12-15 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US10512643B2 (en) 2013-11-05 2019-12-24 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11141416B2 (en) 2013-11-05 2021-10-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10881657B2 (en) 2013-11-05 2021-01-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10688066B2 (en) 2018-03-20 2020-06-23 Antecip Bioventures Ii Llc Bupropion and dextromethorphan for treating nicotine addiction
US11596627B2 (en) 2013-11-05 2023-03-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11285118B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11207281B2 (en) 2013-11-05 2021-12-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10874665B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11419867B2 (en) 2013-11-05 2022-08-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9474731B1 (en) 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11478468B2 (en) 2013-11-05 2022-10-25 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571417B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11590124B2 (en) 2013-11-05 2023-02-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10786469B2 (en) 2013-11-05 2020-09-29 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11007189B2 (en) 2013-11-05 2021-05-18 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617728B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11382874B2 (en) 2013-11-05 2022-07-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11439636B1 (en) 2013-11-05 2022-09-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11497721B2 (en) 2013-11-05 2022-11-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11273133B2 (en) 2013-11-05 2022-03-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
WO2015095713A1 (en) 2013-12-20 2015-06-25 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
CN106699527A (zh) * 2016-12-07 2017-05-24 三峡大学 一种间氯苯丙酮的合成方法
US10925842B2 (en) 2019-01-07 2021-02-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations

Also Published As

Publication number Publication date
FR2081326B1 (xx) 1974-08-30
DE2059618A1 (de) 1971-10-07
NO131127B (xx) 1974-12-30
DE2064934A1 (de) 1971-10-21
ZM14070A1 (en) 1972-08-21
AT307389B (de) 1973-05-25
HK78476A (en) 1976-12-17
RO57979A (xx) 1975-03-15
IE34788L (en) 1971-06-04
NL172148C (nl) 1983-07-18
DE2059618C3 (de) 1981-04-16
IL35781A (en) 1973-06-29
FI53813C (fi) 1978-08-10
IT8047948A0 (it) 1980-02-19
BE759838A (fr) 1971-06-03
FI53813B (fi) 1978-05-02
MTP680B (en) 1971-09-11
JPS4825179B1 (xx) 1973-07-26
EG10507A (en) 1976-03-31
IL35781A0 (en) 1971-02-25
CA977777A (en) 1975-11-11
AT302276B (de) 1972-10-10
PL74637B1 (xx) 1974-12-31
AR192302A1 (es) 1973-02-14
ZA708179B (en) 1972-07-26
PH9351A (en) 1975-10-06
FR2081326A1 (xx) 1971-12-03
CH574907A5 (xx) 1976-04-30
AR198945A1 (es) 1974-07-31
ES386127A1 (es) 1973-12-16
US3819706A (en) 1974-06-25
DK134984C (xx) 1977-07-11
IE34788B1 (en) 1975-08-20
SE377933B (xx) 1975-08-04
CS172338B2 (xx) 1976-12-29
NO131127C (xx) 1975-04-09
YU294570A (en) 1978-10-31
MY7700107A (en) 1977-12-31
NL172148B (nl) 1983-02-16
DE2059618B2 (de) 1980-07-10
DK134984B (da) 1977-02-21
NL7017687A (xx) 1971-06-08
CH569693A5 (xx) 1975-11-28

Similar Documents

Publication Publication Date Title
YU34269B (en) Process for preparing delta-alkylamino-propiophenones
YU198170A (en) Process for preparing novel beta-aryl-2-aminoalkoxy-styrenes
YU34663B (en) Process for preparing novel 1-phenoxy-2-hydroxy-3-cycloalkyl-amino-propanes
YU35867B (en) Process for preparing naphthylalkylamines
YU238570A (en) Process for obtaining amino-alshols
YU33975B (en) Process for preparing bufatrienolide-rhamnoside-acylates
YU201378A (en) Process for obtaining 3-amino-delta2-pyrazoline
YU309570A (en) Process for preparing digitoxigenin-delta-l-thevetoside derivatives
YU34399B (en) Process for preparing thiamphenicol-glycinate acetylcysteinate
YU34027B (en) Process for preparing novel substituted o-anilino-phenethyl-alcohols
YU78170A (en) Process for obtaining novel dimethylaminopropylthiocarbamates
YU34475B (en) Process for preparing 5-hydroxy-or 6-hydroxy-isoquinuclidines
YU144670A (en) Process for preparing substituted shloroacylanilides
YU220170A (en) Process for preparing novel p-amino-alyklbenzene-sulfonamide derivatives
YU183570A (en) Process for preparing 3-chloro-4-n-and-iso-propoxy-ureas
YU201270A (en) Process for preparing phenyl-3-tert.-butyl-5-oxadiazolone-2
YU140970A (en) Process for preparing novel substituted 5-nitro-2-furfurylidene-amino-oxazolidinones
YU35350B (en) Process for preparing bis-formamide derivatives
YU167369A (en) Process for preparing 9delta-fluoro-16-methylene-prednisolone-21-acetate
CS194181B2 (en) Process for preparing beta-anilino-alpha-benzyl-acrylonitriles
YU34191B (en) Process for preparing novel 1-phenoxy-2-hydroxyl3-cycloalkyl-aminopropanes
KR780000171B1 (en) Process for producting-aryl-2aminoalkoxy-styrole
KR780000173B1 (en) Process for producting -aryl-2aminoalkoxy-styrole